Company > Profile

Dr Julian Gilbert

Chief Executive Officer & Founder

Julian is Chief Executive Officer & Co-Founder of Acacia Pharma. He has more than 30 years of commercial and technical experience in the pharmaceutical industry gained at a number of companies including Chiroscience, Mundipharma, British Technology Group (BTG) and Smith Kline & French (now GlaxoSmithKline). Prior to co-founding Acacia Pharma, he was co-founder and commercial director of Arakis which was sold to Sosei in 2005 for £107 million. Arakis successfully developed a pipeline of clinical opportunities and out-licensed its lead project to Novartis (repurposed glycopyrronium for chronic obstructive pulmonary disease (COPD) - now branded Seebri® and Ultibro® Breezhalers®). Julian is one of the inventors on the new use glycopyrronium patent and led the commercialisation to Novartis. He also led the commercialisation of AD923 (sub-lingual fentanyl spray) for cancer breakthrough pain to Mundipharma. He has a degree in pharmacy and a PhD in pharmaceutics both from the University of Nottingham.

< back to Board